Targeting potent warheads to the tumor microenvironment
The pre|CISION® peptide drug conjugate platform. >
Avacta is seeking to expand its partnerships for targeted cancer therapies. >
We’re delighted to be shortlisted as a finalist at the 2024 Scrip Awards in the ‘Best Oncology R&D Advance’ category >
AVA6000 is the first clinical-stage pre|CISION® molecule. It is a peptide drug conjugate that leverages the tumor-specific expression of FAP.
Read more
Latest news
